The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1081
June 26, 2000
View Complete Issue         Table of Contents 2019 
Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome
June 26, 2000 (Issue: 1081)
Alosetron hydrochloride (Lotronex - Glaxo Welcome), a selective serotonin receptor antagonist, has received FDA approval for treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is diarrhea.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Alosetron (Lotronex) For Treatment of Irritable Bowel Syndrome
Article code: 1081a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.